Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.
about
Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanismThe effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjectsLovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exerciseRhabdomyolysis associated with lovastatin and erythromycin use.Bezafibrate induced rhabdomyolysisMacrolide drug interactions: an update.A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients.Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.Rhabdomyolysis and HMG-CoA reductase inhibitors.The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions.Graft vessel disease following heart transplantation: a systematic review of the role of statin therapy.Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs.Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.Clinical response to statins: mechanism(s) of variable activity and adverse effects.Addressing statin adverse effects in the clinic: the 5 Ms.Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.More on lovastatin.Tyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblasts.Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway.Transplantation and lipids.Accelerated graft atherosclerosis after heart transplantation.Myopathic effects of lovastatinCoronary artery disease after heart transplantation: clinical aspects[Severe rhabdomyolysis in a patient receiving lovastatin, danazol, and doxycycline]Fluvastatin-induced rhabdomyolysis.Protective effects of coenzyme Q10 and L-carnitine against statin-induced pancreatic mitochondrial toxicity in rats.The effect of HMG-CoA reductase inhibitors on chronic allograft rejection.Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model.Modeling the effects of commonly used drugs on human metabolism
P2860
Q24603957-32958C20-3D5B-4E8E-A9C0-F6390BE93636Q28361017-EE585255-100A-4012-BE0D-F11C37531853Q33558888-412AFC4C-DD82-46ED-A613-B7923A14EA35Q33558924-6590F224-12D0-443F-B412-AD67B66DAED6Q33564578-5B590E56-3571-428D-AE77-4E76E8DC63C7Q33895235-4E0E318F-83A9-495A-9A30-27F932D17B52Q34346812-6274A240-19CA-4A7D-876B-367EF72E7E37Q34362558-79E10B2A-6B34-4A86-872F-1621DF81BA22Q34382555-0B08689A-B801-45A5-8391-F2DFF7626E3BQ34388588-B1DB798B-0FE5-46A0-AC73-80CA22948899Q34389584-6EDB84D7-5BB1-48DD-9820-9F2219837E27Q35139244-953DF624-5C41-453D-8182-2271730485F2Q35827696-A18EF72E-0671-4F0E-AD51-EA1D20BB4D55Q35953252-28AB1513-A9FB-48FF-9C37-50FF2CDE96CAQ36821282-1E483A26-1859-429A-9EB8-2A95854868A8Q37881964-363E5BA0-FA6F-41C0-B272-C72E6A4FE834Q38207488-24F46084-9E28-4C49-BC86-39714B467F20Q38549355-34CCD305-E42D-4018-9B81-1F4A84C9D015Q40689351-F7B8A272-1748-40A9-A0A5-7E8A6BF18547Q40768932-CB839833-73FE-49DB-B239-E4500456F970Q40921761-F39C546D-AE03-4604-AFA6-2941D1ABCDAEQ40938703-33C90BD3-C114-4068-B287-E463F0E6BF4CQ40992838-FC61CE62-3758-4707-85B0-0181830E07F0Q41513586-12AA1032-3CF8-40C3-8D50-631E576F45A4Q41987299-B45FEBD1-710C-496E-888E-7666D0441700Q42542374-1EBB2766-A833-48CF-8ECF-3FBFF349D55DQ42577957-ECDB275F-88E1-496C-861D-B27F9A46C205Q43167348-5DFB9139-1E04-43C8-B822-844AEC989DAFQ44229921-3970CC9D-F10D-458C-94B6-413EBC2307A9Q46035508-B79109C9-7ABE-40F6-829B-F622F689AB5DQ46576591-6D44D99C-111E-4A7F-B11C-C6627D4068FEQ51937078-38D5F39B-431D-4D84-87ED-423ED6C2CD7AQ57004702-F7CC1492-4486-4C49-919D-25F50C9D60A8
P2860
Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Rhabdomyolysis and renal injur ...... cardiac transplant recipients.
@en
Rhabdomyolysis and renal injur ...... cardiac transplant recipients.
@nl
type
label
Rhabdomyolysis and renal injur ...... cardiac transplant recipients.
@en
Rhabdomyolysis and renal injur ...... cardiac transplant recipients.
@nl
prefLabel
Rhabdomyolysis and renal injur ...... cardiac transplant recipients.
@en
Rhabdomyolysis and renal injur ...... cardiac transplant recipients.
@nl
P2093
P1476
Rhabdomyolysis and renal injur ...... cardiac transplant recipients.
@en
P2093
C L Corpier
E D Lederer
M A Quinones
S W Schmidt
P304
P356
10.1001/JAMA.1988.03410020105038
P407
P577
1988-07-01T00:00:00Z